Overview

• The phase 3 Serena-6 trial enrolled over 3,000 patients with hormone-positive, HER2-negative breast cancer across 23 countries and demonstrated a 56% reduction in disease progression or death risk with camizestrant.
• Patients receiving camizestrant plus a CDK4/6 inhibitor experienced median progression-free survival of 16 months compared with about 9 months under standard therapy.
• Researchers used blood tests to detect ESR1 mutations and switched patients early to camizestrant before tumors showed progression on scans.
• The camizestrant combination was well tolerated, with just 1% of participants discontinuing treatment due to side effects.
• Camizestrant has received FDA breakthrough therapy designation and is now under expedited US regulatory review, marking a potential shift in precision breast cancer care.